18 May 2007
Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: Safety and symptom control
Zbigniew Serafin, Maciej Karolkiewicz, Piotr Strześniewski, Władysław Lasek, Michał Bryczkowski, Zbigniew WolskiMed Sci Monit 2007; 13(1): 98-104 :: ID: 482390
Abstract
Background: Primarily palliative renal embolization is a relatively rare procedure which is indicated in patients with unresectable kidney malignancies and in patients in poor general condition. The aim of this paper was to evaluate the role of primarily palliative transarterial renal embolization for the treatment of inoperable patients with renal cell carcinoma, assessing the indications, safety, and efficacy of this procedure.Material and Methods: Seventy-three patients scheduled for palliative embolization between 1998 and 2005 were retrospectively analyzed regarding their medical history, the procedure report, and data from the early postoperative period. Results: Sixty-six of the 73 patients presented with renal cell carcinoma stage IV. The most common indication for embolization was hematuria (34%), followed by flank pain (32%), prophylaxis in stage IV (25%), lack of consent for surgery (7%), and poor general condition (3%). Embolizations were performed under local anesthesia with a mixture of enbucrilate and iodinated oil, with the use of additional embolizing materials in two cases. The procedure eliminated hematuria in 100% of cases and removed the loin pain completely in 72%. Migration of the embolizing material was observed in 10% of cases, and in 4% it resulted in symptomatic occlusion of the lower extremity distal arteries. Postembolic syndrome was noted in 92% of the patients. Conclusions: Percutaneous palliative embolization with enbucrilate is a safe and effective method of treating patients with unresectable renal cell carcinoma. The potential effect of the embolization on cancer progression and improvement of survival in these patients still requires prospective investigation.
Keywords: Aged, 80 and over, Carcinoma, Renal Cell - therapy, Embolization, Therapeutic, Enbucrilate - therapeutic use, Kidney - pathology
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Laboratory Research
Comparative Evaluation of the Dimensional Accuracy of Silicone-Based Putty Reline Impressions with Differen...Med Sci Monit In Press; DOI: 10.12659/MSM.946537
Clinical Research
Ankle-Brachial Index as a Predictor of Acute Ischemic Cerebrovascular Event After Central Retinal Artery Oc...Med Sci Monit In Press; DOI: 10.12659/MSM.945937
Review article
COL3A1 Gene Polymorphism and Its Impact on Female Pelvic Organ ProlapseMed Sci Monit In Press; DOI: 10.12659/MSM.946367
Clinical Research
Quantifying Gait Asymmetry in Stroke Patients: A Statistical Parametric Mapping (SPM) ApproachMed Sci Monit In Press; DOI: 10.12659/MSM.946754
Most Viewed Current Articles
17 Jan 2024 : Review article 6,962,292
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 699,764
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 22,978
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 17,753
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912